Pharm Sci Anti-coag Flashcards
Charge of UFH
Negatively
UFH
From pig, glycosaminoglycan consisting of sulfated repeating disaccharide units
MW of UFH
12,000 to 15,000
What are the natural anticoagulants?
Protein C and S
MOA of UFH
Binds anti-thrombin, undergoes a conformational change, it increases the infinity for thrombin, the complex which increases thrombin inhibition- means that it increases the inhibitory activity of anti thrombin
Also binds and I activates factor Xa- no tail involved
MOA of LMWH
Pentasaccharide structure binds anti thrombin; has shorter tail so mainly inactivates factor Xa
MOA of Fondaparinux
No tail so only inactivates Factor Xa
Common denominator of UFH, LMWH, and Fonda?
All bind anti thrombin
ADR of UFH
High risk of bleeding, hypersensitivity, HIT
Long term use: osteoporosis, fractures, decreased effectiveness of clotting
ADR of LMWH
Bleeding, hematoma, lower risk of HIT than UFH avoid if have history of HIT
ADR of Fondaparinux
Bleeding
How are anti-coagulant effects mediated for UFH, LMWH, and Fondaparinux?
By binding through Anti-thrombin
LMWH inactivate what better then what?
Inactivate factor 10a better than thrombin b/c of shorter tail
Type 1 HIT
Presents 2 days after heparinuse, platelet count normalizes after continuous heparin use, no immune disorder
HIT treatment
D/c all heparin therapy
Use: refiudam, argatroban, orgaran
Type 2 HIT
Immune mediated disorder that occurs that occurs 4 to ten days after heparin exposure, life and limb threatening thrombotic complications, norm platelets decrease by fifty percent, skin lesions at injection site, marked by VTE
Rivaroxaban
Direct factor Xa inhibitor
Po daily with largest meal of day no monitoring
Hepatic and renal elimination
Cyp3a4 metabolism to inactive metabolites
Pgp substrate
Half life and peak effect time for rivaroxaban?
Half life 7-11 hrs
Peak effect 2-4 hrs
Precautions for rivaroxaban
Risk of hematomas
Caution with renal or hepatic impairment
Anti platelets or NSAIDS increase bleeding
Rebound thromboembolic events
No antidote
Expensive
Apixaban
Direct factor Xa selective, po bid, no monitoring, hepatic and renal elimination, cyp3a4 metabolism to inactive metabolites, pgp substrate
Expensive,
Caution with Apixaban
Caution with Renal or hepatic impairment
Anti platelets and NSAIDs increase bleeding
Rebound thromboembolic events
No antidote
Expensive
Edoxaban
Not yet approved
Direct Xa inhibitor
Oral
3a4 and pgp substrate renal component
Dabigatran
Direct thrombin inhibitor
Doesn’t require anti thrombin to function
Selective
Inhibits both circulating and clot bound thrombin
Oral bid, no monitoring
Ester prodrug requiring ester hydrolysis for activation
80 percent elimin in urine
Undergoes glucuronidation